These days Bristol-Myers Squibb Co.'s immunology expertise is most often associated with its immuno-oncology blockbusters, but the company is also focused on expanding its position in autoimmune diseases, which is anchored by Orencia (abatacept).
In fact, Orencia – a selective T-cell co-stimulation modulator targeting CD80 and CD86 – won its initial US FDA approval in 2005, so it's been on the market far longer than the breakthrough immuno-oncology therapies Yervoy (ipilimumab) and Opdivo (nivolumab)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?